MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Clinical trials for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug could slow liver scarring in NASH cirrhosis patients
Disease control Recruiting nowThis study tests a drug called efruxifermin in about 2,150 adults with liver cirrhosis (severe scarring) caused by NASH/MASH, a type of fatty liver disease. Participants will receive either the drug or a placebo to see if it can prevent serious liver events and improve fibrosis. …
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated May 26, 2026 05:32 UTC
-
New drug HU6 targets fatty liver disease in Mid-Stage trial
Disease control Recruiting nowThis study tests a new drug, HU6, in 180 adults aged 30 and older with MASH, a serious fatty liver condition. The goal is to see if HU6 is safe and can reduce liver fat compared to a placebo over 26 weeks. Participants will be randomly assigned to one of four groups, and neither …
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Rivus Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 05:27 UTC
-
New hope for liver transplant patients with fatty liver disease
Disease control Recruiting nowThis study tests a drug called resmetirom in 120 people who have had a liver transplant and now have a fatty liver condition called MASH. Participants take the drug or a placebo daily for 28 weeks. The goal is to see if the drug safely reduces liver fat and stiffness. This is a p…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
Could a common heart drug be the key to reversing fatty liver disease?
Disease control Recruiting nowThis study tests if a low dose of digoxin, a drug currently used for heart conditions, can help people with NASH (a severe type of fatty liver disease). About 144 adults with NASH and liver scarring will take oral digoxin for a period. The goal is to see if the drug can reverse t…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New MASH drug trial aims to tame fatty liver disease
Disease control Recruiting nowThis early-stage study tests a new drug called TGM-312-SC01 in healthy adults and people with MASH, a type of fatty liver disease. The main goal is to check the drug's safety and how the body processes it. About 99 participants will receive either the drug or a placebo to gather …
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE1, PHASE2 • Sponsor: Tangram Therapeutics Plc • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
New hope for fatty liver: drug trial targets scarring
Disease control Recruiting nowThis study tests a drug called resmiterom in 165 adults with MASH, a type of fatty liver disease that can lead to scarring. Participants must have at least one metabolic issue like diabetes or obesity. The goal is to see if the drug safely reduces liver damage and improves thyroi…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE4 • Sponsor: Nabiqasim Industries (Pvt) Ltd • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
Fatty liver linked to colon polyp genes? new study investigates
Knowledge-focused Recruiting nowThis study looks at colon polyps in people with a type of fatty liver disease (MASH) compared to those without it. Researchers want to find gene differences that might signal higher-risk polyps. About 100 adults already scheduled for polyp removal will donate a small piece of tis…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Sponsor: Shanghai East Hospital • Aim: Knowledge-focused
Last updated May 26, 2026 05:35 UTC
-
New registry tracks Rezdiffra's safety in pregnant NASH patients and their infants
Knowledge-focused Recruiting nowThis study is a registry that follows women with NASH who took Rezdiffra during pregnancy or while breastfeeding, along with their babies up to 12 months old. It does not give any treatment but collects information on pregnancy outcomes, birth defects, and infant growth and safet…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated May 26, 2026 04:36 UTC